Sangamo BioSciences Inc. (NASDAQ:SGMO) Receives $17.75 Consensus Target Price from Analysts
Sangamo BioSciences Inc. (NASDAQ:SGMO) has received an average rating of “Buy” from the eight brokerages that are covering the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.75.
Several research analysts recently weighed in on the stock. Jefferies Group restated a “buy” rating on shares of Sangamo BioSciences in a research report on Friday, August 5th. Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday, August 10th. Janney Montgomery Scott cut shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $15.00 to $8.00 in a research report on Thursday, August 4th. Finally, Zacks Investment Research cut shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th.
Several hedge funds have recently added to or reduced their stakes in SGMO. BlackRock Fund Advisors boosted its stake in Sangamo BioSciences by 5.6% in the second quarter. BlackRock Fund Advisors now owns 2,713,404 shares of the biopharmaceutical company’s stock worth $15,711,000 after buying an additional 145,060 shares in the last quarter. Vanguard Group Inc. boosted its stake in Sangamo BioSciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 2,694,393 shares of the biopharmaceutical company’s stock worth $15,601,000 after buying an additional 234,286 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Sangamo BioSciences by 35.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $14,475,000 after buying an additional 650,000 shares in the last quarter. State Street Corp boosted its stake in Sangamo BioSciences by 21.4% in the first quarter. State Street Corp now owns 2,251,763 shares of the biopharmaceutical company’s stock worth $13,622,000 after buying an additional 397,097 shares in the last quarter. Finally, Foresite Capital Management III LLC purchased a new stake in Sangamo BioSciences during the first quarter worth approximately $3,296,000. Institutional investors and hedge funds own 65.24% of the company’s stock.
Shares of Sangamo BioSciences (NASDAQ:SGMO) opened at 4.72 on Monday. The firm’s market cap is $333.32 million. The company’s 50-day moving average price is $4.58 and its 200-day moving average price is $5.78. Sangamo BioSciences has a 52-week low of $4.08 and a 52-week high of $9.91.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.14. Sangamo BioSciences had a negative return on equity of 36.08% and a negative net margin of 261.81%. The company earned $3.70 million during the quarter, compared to the consensus estimate of $5.38 million. During the same quarter last year, the firm earned ($0.17) EPS. The business’s revenue for the quarter was down 56.0% on a year-over-year basis. Equities analysts expect that Sangamo BioSciences will post ($1.11) earnings per share for the current fiscal year.
About Sangamo BioSciences
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.